Last reviewed · How we verify
NCT03485547
Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Completed
Phase 1
Last updated 2 February 2026
What this trial tests
Phase 1 trial testing Venetoclax in Blastic Plasmacytoid Dendritic Cell Neoplasm in 5 participants. Completed in 16 April 2025.
Timeline
23 August 2018
Primary endpoint
10 January 2022
10 January 2022
16 April 2025
Quick facts
| Lead sponsor | Dana-Farber Cancer Institute |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 5 |
| Start date | 23 August 2018 |
| Primary completion | 10 January 2022 |
| Estimated completion | 16 April 2025 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Venetoclax (venetoclax) — full drug profile →
Conditions studied
- Blastic Plasmacytoid Dendritic Cell Neoplasm — all drugs for Blastic Plasmacytoid Dendritic Cell Neoplasm →
Sponsor
Dana-Farber Cancer Institute
Who can join
18 and older, any sex, with Blastic Plasmacytoid Dendritic Cell Neoplasm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This research study is studying a drug as a possible treatment for BPDCN. The intervention involved in this study is: Venetoclax
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark.
Taylor J, Haddadin M, Upadhyay VA, Grussie E, et al · · 2019 · cited 69× · PMID 31243042 · DOI 10.1182/blood.2019001144 -
Novel Apoptosis-Inducing Agents for the Treatment of Cancer, a New Arsenal in the Toolbox.
Lim B, Greer Y, Lipkowitz S, Takebe N. · · 2019 · cited 61× · PMID 31370269 · DOI 10.3390/cancers11081087 -
Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patients.
Laribi K, Baugier de Materre A, Sobh M, Cerroni L, et al · · 2020 · cited 60× · PMID 33027528 · DOI 10.1182/bloodadvances.2020002474 -
Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapies.
Cuglievan B, Connors J, He J, Khazal S, et al · · 2023 · cited 41× · PMID 37452102 · DOI 10.1038/s41375-023-01968-z -
Emerging Therapies for Acute Myelogenus Leukemia Patients Targeting Apoptosis and Mitochondrial Metabolism.
Castelli G, Pelosi E, Testa U. · · 2019 · cited 25× · PMID 30813354 · DOI 10.3390/cancers11020260 -
Venetoclax in relapsed/refractory blastic plasmacytoid dendritic cell neoplasm with central nervous system involvement: a case report and review of the literature.
Albiol N, Novelli S, Mozos A, Pratcorona M, et al · · 2021 · cited 15× · PMID 34172079 · DOI 10.1186/s13256-021-02939-7 -
Clinical Insights into the Management of Blastic Plasmacytoid Dendritic Cell Neoplasm.
Zhang Y, Sokol L. · · 2022 · cited 12× · PMID 35789956 · DOI 10.2147/cmar.s330398 -
The mitochondrial anti-apoptotic dependencies of hematologic malignancies: from disease biology to advances in precision medicine.
Ferrarini I, Rigo A, Visco C. · · 2022 · cited 12× · PMID 35045693 · DOI 10.3324/haematol.2021.280201
Verify or expand the search:
- PubMed search for NCT03485547
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Venetoclax
Trials testing the same drug.
- NCT07425808 — FLT3-ITD Targeted Therapy in Fit AML Patients · Phase 2, PHASE3 · not yet recruiting
- NCT07437950 — Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A Myel · Phase 2 · not yet recruiting
- NCT07175415 — HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological · Phase 1, PHASE2 · not yet recruiting
- NCT07513129 — A Phase 1 Study Of Venetoclax, Dexamethasone, Bortezomib, And Daratumumab (VDBD) For Adolescent And Young Adult Patients · Phase 1 · not yet recruiting
- NCT07511062 — Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML · Phase 1 · not yet recruiting
Other recruiting trials for Blastic Plasmacytoid Dendritic Cell Neoplasm
Currently open trials in the same condition.
- NCT06013423 — Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hem · Phase 2 · recruiting
- NCT04216524 — Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm · Phase 2 · recruiting
- NCT03779854 — Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers · Phase 2 · recruiting
- NCT03386513 — Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN · Phase 1, PHASE2 · active not recruiting
- NCT03113643 — SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplas · Phase 1 · recruiting
Other Dana-Farber Cancer Institute trials
Trials by the same sponsor.
- NCT07519200 — Sexual Health and Rehabilitation for Women With Metastatic Breast Cancer (SHARE-MC): An Educational Intervention · NA · not yet recruiting
- NCT07499999 — Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk fo · Phase 2 · not yet recruiting
- NCT05825469 — Development and Testing of Nutritional Algorithms (NACHO) · NA · not yet recruiting
- NCT07516353 — my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults · NA · not yet recruiting
- NCT07513324 — Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0) · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT03485547 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dana-Farber Cancer Institute
- Last refreshed: 2 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03485547.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing